Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-02-06
2007-02-06
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S197000, C544S198000, C544S207000, C544S208000, C544S216000, C544S219000, C540S524000, C514S217050, C514S241000
Reexamination Certificate
active
10390485
ABSTRACT:
The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.
REFERENCES:
patent: 3290305 (1966-12-01), Schmitz
patent: 3758471 (1973-09-01), Irikura et al.
patent: 3867383 (1975-02-01), Winter
patent: 4617390 (1986-10-01), Hoppe et al.
patent: 5062882 (1991-11-01), Newton et al.
patent: 5346691 (1994-09-01), Raspanti
patent: 5470921 (1995-11-01), Kaul et al.
patent: 5759525 (1998-06-01), Raspanti et al.
patent: 5801224 (1998-09-01), Narayan et al.
patent: 6117996 (2000-09-01), Lowe et al.
patent: 6123763 (2000-09-01), Kamikubo et al.
patent: 6150360 (2000-11-01), Daeyaert et al.
patent: 6239071 (2001-05-01), Giencke et al.
patent: 6284710 (2001-09-01), Riebel et al.
patent: 6491617 (2002-12-01), Ogle et al.
patent: 6645964 (2003-11-01), Mailliet et al.
patent: 2002/0065270 (2002-05-01), Moriarty et al.
patent: 19531084 (1997-02-01), None
patent: WO 97/08156 (1997-03-01), None
patent: WO 99/31088 (1999-06-01), None
patent: WO 99/36410 (1999-07-01), None
patent: WO01/47897 (2001-05-01), None
patent: WO 01/40218 (2001-06-01), None
patent: WO 01/47897 (2001-07-01), None
patent: WO 01/47921 (2001-07-01), None
patent: WO 03/024926 (2003-03-01), None
patent: WO 04/026844 (2004-04-01), None
Bennet, J. Ed., et al., Cecil Textbook of Medicine, 20thEd., 1996, 1001-1010, W. B. Saunders Company.
Axford, J., “Glycosylation and Rheumatic Disease”, Biochimica et Biophysica Acta, 1999, 219-229, 1455, Elsevier Science B.V.
Stern, R., “Devising A Pathway For Hyaluronan Catabolism: Are We There Yet?”, Glycobiology, 2003, 105R-115R, vol. 13, No. 12, Oxford University Press.
Alexander Christopher W.
Campbell Karen A.
Pillarisetti Sivaram
Saxena Uday
Timmer Richard T.
Balasubramanian Venkataraman
Reddy US Therapeutics Inc.
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Methods and compositions of novel triazine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions of novel triazine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions of novel triazine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3818301